# Liquidia Corp > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Liquidia Corp). ## Overview Liquidia Corp is a U.S.-based biopharmaceutical company focused on rare cardiopulmonary diseases, especially pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It develops and commercializes inhaled therapies built around its proprietary PRINT particle-engineering platform, with current revenue coming from YUTREPIA and a U.S. profit-sharing promotion agreement with Sandoz. ## Products & services • YUTREPIA (treprostinil) inhalation powder • Promotion agreement for Sandoz Treprostinil Injection • PRINT particle-engineering platform • Development of L606 for PAH / PH-ILD • Research, manufacturing, and commercialization services - **Commercial products** (94%) — Approved and marketed therapies sold directly to patients and providers, led by YUTREPIA. - **Promotion agreement revenue** (6%) — Profit-sharing revenue from commercial activities tied to Sandoz Treprostinil Injection in the U.S. - **Pipeline and platform development** (0%) — Development of L606 and other PRINT-enabled product opportunities that are not yet commercial. - YUTREPIA inhalation powder for PAH and PH-ILD - Sandoz Treprostinil Injection promotion and profit share - PRINT technology for uniform particle engineering - L606 product candidate for cardiopulmonary disease - R&D, manufacturing, and commercial support for respiratory drugs ## Customers Liquidia sells into the U.S. cardiopulmonary specialty care ecosystem, where physicians treat patients with PAH and PH-ILD and pharmacies/distributors handle access and reimbursement. Its commercial model depends on prescribers, hospital pharmacies, and payors that influence adoption of inhaled treprostinil therapies, while Sandoz-related revenue comes from the U.S. generic treprostinil market. - **PAH specialty prescribers** (primary) — Pulmonary hypertension specialists who prescribe YUTREPIA or support Treprostinil Injection use because of efficacy, convenience, and dosing profile. - **PH-ILD treatment centers** (primary) — Clinicians treating PH-ILD patients who may adopt YUTREPIA for an inhaled treprostinil option in a difficult disease area. - **Specialty and hospital pharmacies** (secondary) — Pharmacies that distribute the product and manage fulfillment, reimbursement, and patient access. - **Payers and reimbursement stakeholders** (primary) — Commercial and government payors that determine formulary access, rebates, and patient affordability. - **Sandoz commercial partner** (secondary) — Sandoz buys promotion support and shares profits from Treprostinil Injection sales in the U.S. - Specialist physicians treating PAH and PH-ILD patients - Hospital pharmacies and specialty pharmacies dispensing inhaled therapies - Payers and reimbursement stakeholders affecting access and uptake - Patients needing inhaled treprostinil with easier administration - Sandoz as a commercial partner for Treprostinil Injection ## Geography Liquidia is overwhelmingly U.S.-centric: YUTREPIA commercialization began in the United States, and the Sandoz promotion agreement also relates to U.S. Treprostinil Injection sales. The company’s operations are concentrated in Morrisville, North Carolina, with laboratory, manufacturing, and office leases supporting development and commercialization activities. - United States is the core commercial market for YUTREPIA - U.S. Treprostinil Injection profit share is tied to Sandoz sales - Morrisville, North Carolina is the main operating base - Laboratory, manufacturing, and office leases support U.S. operations - Geographic concentration increases exposure to U.S. reimbursement and litigation ## Strategy Liquidia’s near-term strategy is to scale YUTREPIA after its May 2025 FDA approval and June 2025 launch, while using a targeted field force to build prescriber and reimbursement adoption. Longer term, the company is trying to extend its PRINT platform and advance L606 and other pipeline opportunities to broaden its respiratory and vascular disease franchise. - **Scale YUTREPIA commercialization** (short-term) — Approved product sales are now the main direct revenue engine and must offset development spending. - **Grow reimbursement and access** (short-term) — Adoption depends on payor coverage, gross-to-net performance, and specialty pharmacy execution. - **Advance pipeline and platform value** (medium-term) — L606 and PRINT-based programs are needed to diversify the company beyond a single commercial product. - Expand YUTREPIA adoption after FDA approval and launch - Use targeted sales coverage in PAH and PH-ILD specialty channels - Defend and grow U.S. treprostinil market share versus competing therapies - Advance L606 and other PRINT-enabled pipeline assets - Leverage Sandoz profit share while building direct commercial revenue ## Risks Liquidia faces high execution risk because it depends on a newly launched product, a narrow disease focus, and third-party manufacturing and supply chains. It also faces litigation, reimbursement pressure, and financing risk typical of development-stage biopharma companies, while its U.S. operating concentration makes disruptions in one geography especially important. - **Single-source manufacturing and supply dependence** [high] — The company relies on third parties for active ingredient, device, encapsulation, and packaging, so any disruption can delay supply and commercialization. - **Commercial launch and reimbursement risk** [high] — YUTREPIA is newly launched, so uptake depends on physician adoption, payor coverage, and gross-to-net performance. - **Patent and Hatch-Waxman litigation** [high] — 505(b)(2) products can face patent disputes that delay approval, restrict labeling, or force costly settlements. - **Financing and dilution risk** [high] — The company has significant development and commercialization needs and may need additional capital on unfavorable terms. - **Operational concentration in North Carolina** [medium] — A localized disruption could affect lab, manufacturing, and office operations and is not easily diversified. - YUTREPIA launch risk if adoption or reimbursement is slower than expected - Dependence on single suppliers for key product components and manufacturing steps - Litigation and Hatch-Waxman/IP risk could delay or limit commercialization - Need for external financing if cash burn remains high - U.S. concentration exposes the business to regulatory and reimbursement changes ## Accounting Liquidia’s reported revenue is sensitive to launch timing, gross-to-net deductions, and the mix between product sales and promotion-agreement service revenue. Investors should also watch manufacturing commitments, lease obligations, and litigation/contingency estimates because these can materially affect cash needs and reported liabilities. - **Revenue recognition and gross-to-net deductions** — Affects product sales timing and net revenue margin - **Promotion agreement revenue estimation** — Can cause volatility in service revenue and margins - **Manufacturing supply commitments** — Affects liquidity and operating flexibility - **Operating lease accounting** — Affects balance sheet lease liabilities and future cash commitments - **Legal proceedings and contingencies** — May require reserves or disclosure of contingent liabilities - Revenue recognition depends on rebates, chargebacks, discounts, and returns - Product launch timing creates sharp quarter-to-quarter revenue comparability swings - Promotion-agreement revenue depends on Sandoz sales and managed care adjustments - Manufacturing commitments create fixed future cash obligations - Lease and litigation estimates affect liabilities and expense recognition --- *Last updated: 2026-04-28T20:23:10.874426+00:00*